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ABSTRACT
Objective: To evaluate the cost-effectiveness of disease-modifying thera-
pies (DMTs) for the management of multiple sclerosis (MS) compared to
best supportive care in the United States.
Methods: Cost-effectiveness analysis was undertaken using a state tran-
sition model of disease natural history and the impact of DMTs for the
representative Medicare beneﬁciary with MS. Costs and outcomes were
evaluated from the health-care payer perspective using a 50-year time
horizon. Natural history data were drawn from a longitudinal cohort
study. The effectiveness of the DMTs was evaluated through a systematic
review. Utility data were taken from a study of patients with clinically
deﬁnite MS in Nova Scotia. Resource use and cost data were derived from
the Sonya Slifka database and associated literature.
Results: When based on placebo-controlled evidence, the marginal cost-
effectiveness of interferon beta (IFNb) and glatiramer acetate compared
to best supportive care is expected to be in excess of $100,000 per
quality-adjusted life-year gained. When evidence from head-to-head trials
is incorporated into the model, the cost-effectiveness of 6 MIU IFNb-1a is
expected to be considerably less favorable. Treatment discontinuation
upon progression to Expanded Disability Status Scale 7.0 is expected to
improve the cost-effectiveness of all DMTs.
Conclusions: Further research is required to examine the long-term
clinical effectiveness and cost-effectiveness of these therapies. There is
no deﬁnitive guidance in the United States concerning discontinuation
of DMTs; this study suggests that the prudent use of a treatment
discontinuation rule may considerably improve the cost-effectiveness of
DMTs.
Keywords: cost-utility analysis, decision analysis model, economic analy-
sis, multiple sclerosis.
Introduction
Multiple sclerosis (MS) is one of the most common neurological
conditions affecting young adults, and is two to three times more
common in women than men [1,2]. Around 400,000 people
in the United States suffer from MS, and its prevalence in the
northern states is reported to be higher than in the southern
states [2]. The underlying early pathogenic mechanisms include
inﬂammation, demyelination, and axonal loss, whereas chronic
axonal degeneration predominates later. The disease is charac-
terized by a variety of symptoms including pain, fatigue,
impaired muscle control, balance and postural problems, cogni-
tive impairments, and optic neuritis [1,3]. The disease has a
considerable impact upon a patient’s quality of life, and the costs
of disease management are substantial.
Progressive neurological disability resulting from MS is com-
monly measured using the Expanded Disability Status Scale
(EDSS), an ordinal scale ranging from EDSS 0 (normal neuro-
logical examination) to EDSS 10 (death due to MS) [4]. Disease
management focuses on slowing progression and prevent-
ing relapse as well as controlling symptoms. Interferon beta
(IFNb-1a and IFNb-1b) and glatiramer acetate (GA), which are
known as “disease-modifying therapies” (DMTs), are thought to
slow the progression of the disease and reduce the number and
severity of relapses experienced. IFNb-1a, IFNb-1b, and GA have
been approved for the treatment of relapsing–remitting MS
(RRMS). IFNb-1b has also been approved for secondary progres-
sive MS (SPMS). Until 2002, Medicare coverage for these thera-
pies to treat MS was sporadic, varying by carrier depending
on their interpretation of whether a drug was usually self- or
physician-administered. In 2002, the Centers for Medicare
and Medicaid Services (CMS) clariﬁed the deﬁnition of self-
administered drugs, allowing for coverage of IFNb-1a for treat-
ment of MS if administered intramuscularly by a physician.
Subcutaneous IFNb-1a administered by the patient was not
covered. The Medicare Replacement Drug Demonstration
(MRDD) expanded coverage to all self-administered treatments
nationwide on a temporary basis before the new prescription
drug beneﬁt was introduced [5].
This article reports a study requested by the CMS to evaluate
the cost-effectiveness of expanded drug coverage to Medicare.
We report the methods and results of a mathematical model
developed to estimate the marginal cost-effectiveness of IFNb
and GA as compared to best supportive care for RRMS and
SPMS from the perspective of the US health-care payer. The
cost-effectiveness of these therapies from the perspective of the
CMS was also examined.
Methods
Model Scope and Structure
The model estimates the costs and health outcomes for seven
active treatment options as compared to best supportive care.
For RRMS only, the following interventions are evaluated:
IFNb-1a 6 MIU (physician-administered), IFNb-1a 6 MIU (self-
administered), IFNb-1a 22 mg, IFNb-1a 44 mg, IFNb-1b 8 MIU,
and GA 20 mg. For these six options, management of SPMS
is assumed to include best supportive care only. The cost-
effectiveness of a combined option of IFNb-1b 8 MIU for the
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treatment of both RRMS and SPMS is also evaluated. Other
DMTs such as natalizumab and mitoxantrone were excluded
from the analysis on two grounds. First, natalizumab and mitox-
antrone were not covered by the MRDD at the time of the
analysis and therefore were not relevant to the CMS’ decision
problem. Second, natalizumab is used in patients with rapidly
evolving MS who have high disease activity; this subgroup of MS
patients is likely to have a very different natural history to the
broader RRMS population.
Details of the model structure have been reported in detail
elsewhere [6–8]. Brieﬂy, the model simulates the natural history
of MS using the state transition methodology, modeling indi-
vidual EDSS states from 0 through 10 in RRMS, and from EDSS
2.0 through 10 in SPMS. Disease course, cost, and utilities with
and without treatment are assessed using an annual cycle length
over a time horizon of 50 years (the remaining lifetime of the
model cohort irrespective of treatment option). Patients enter
the model aged 51 years, with a baseline distribution across the
RRMS EDSS states based on a sample of patients from the Sonya
Slifka data set who represented the Medicare MS population
[9,10]. All patients subsequently experience progressive disability
as measured on the EDSS according to the transition probabili-
ties derived from the London Ontario Cohort natural history
data set [11,12]. The model assumes that disease progression
is independent of time since onset, while the age-speciﬁc risk of
death is modeled using time-dependent probabilities. EDSS-
speciﬁc relapse rates without DMT were derived from an analysis
of a long-term observational study of MS relapse [13].
During any given model cycle, patients can remain in their
current EDSS state, progress one or more EDSS states, transit to
an SPMS health state, discontinue therapy, or die. At the point of
treatment cessation, patients are assumed to retain any previ-
ously accrued beneﬁts of DMT in terms of delayed disease pro-
gression (rather than reverting to their expected EDSS had they
never received treatment) and subsequently progress according to
the natural history transition rates [11]. Disease management
costs are associated with spending one cycle in each individual
EDSS health state. Each EDSS state is also assigned a speciﬁc
utility score which describes the mean level of health-related
quality of life (HRQoL) associated with that degree of disability.
Within any EDSS state, patients may also experience relapse,
which has a temporary detrimental impact upon HRQoL and
incurs additional medical management costs. The “on treat-
ment” and “best supportive care” cohorts progress at different
rates, as determined by instantaneous hazard rates estimated
using current clinical effectiveness evidence. Consequently, the
two cohorts accrue different costs and quality-of-life proﬁles;
the marginal cost-effectiveness of each option is estimated as the
additional total costs divided by the additional quality-adjusted
life-years (QALYs) gained for each treatment strategy as com-
pared to best supportive care.
The model employs the following key assumptions:
1. Patients enter the model aged 51 years [9,10]
2. The model simulates the lifetime experience of patients with
RRMS and SPMS disease courses only. The simulation is
continued until all patients within the model have died.
3. All transitions within the model are progressive (patients
cannot experience improvements on the EDSS).
4. The effectiveness of DMT is assumed to continue only for
the period in which the patient is on therapy.
5. A “retained effect” of treatment on both progression and
relapse beyond the duration of the trials included in the
clinical effectiveness review is modeled. Any patient who
discontinues therapy subsequently progresses according to
natural history rates but retains any previously accrued
beneﬁts at no additional cost of therapy.
6. The relative hazards of disease progression and the relative
risks of relapse attributable to DMTs do not deteriorate or
increase over time.
7. The annual risk of “all-cause” mortality for the MS cohort
is assumed to be the same as a normal healthy population.
8. Patients may continue to receive DMT until they drop off
therapy due to side effects, lack of efﬁcacy or until progres-
sion to SPMS or death. The impact of discontinuing therapy
upon progression to EDSS 7.0 is explored in the scenario
analysis.
Evidence Used to Inform Model Parameters
Effectiveness Evidence
A systematic review was undertaken to identify all studies report-
ing progression and relapse outcomes for IFNb and GA in com-
parison to placebo or another DMT in RRMS and SPMS. The
systematic review identiﬁed ﬁve placebo-controlled trials [14–23]
and two head-to-head trials [24,25]; the inclusion and exclusion
criteria are summarized in Table 1. The methods and results of
this systematic review are available from the full study report
[26]. Key clinical outcomes included time-to-disease progression,
relapse rates, and the incidence of adverse events. Relative hazard
ratios for disease progression were estimated using Kaplan–
Meier progression-free survival curves or using relevant narrative
data from the trial publications. EDSS progression hazard ratios
were estimated assuming that EDSS progression-free survival is
exponentially distributed. Relative risks of relapse for the DMTs
were estimated from annualized relapse rates for each treatment
group.
Evidence on EDSS progression hazards and relapse rates
from placebo-controlled and head-to-head trials of the disease
modifying therapies were also synthesized within two Bayesian
mixed treatment comparison models using WinBUGS software
[14–25]. The WinBUGS progression model includes a random
effects term which allows for between-trial heterogeneities. The
WinBUGs relapse model uses a ﬁxed effect comparison; owing
to a lack of published evidence, the relapse model did not allow
for between-trial heterogeneities. A summary of key model
parameters is presented in Table 2.
Table 1 Systematic review inclusion and exclusion criteria
Inclusion criteria
Population Adults with RRMS or SPMS, eligible for treatment with
IFNb or GA.
Interventions (1) GA 20 mg, daily subcutaneous injection; (2) IFNb-1a
22 mg subcutaneous injection 3 times a week; (3) IFNb-
1a 44 mg, subcutaneous injection 3 times a week;
(4) IFNb-1a 6 MIU, intramuscular injection once per week;
(5) IFNb-1b 8 MIU, subcutaneous injection every
other day.
Comparators Placebo, or another disease-modifying therapy in instances
where head-to-head trials were available.
Outcomes EDSS disease progression rates; relapse rates; Health-
related quality of life; adverse events/treatment-related
toxicities; study withdrawals and dropouts.
Study design Randomized controlled trials.
Exclusion criteria Studies were excluded if off-label doses or administrations
of IFNb or GA were employed. Studies of other
medications for MS not listed as included interventions
were excluded. Clinical trials which did not report
EDSS progression data were also excluded from the
systematic review.
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HRQoL
Health utilities associated with individual EDSS states were
estimated from a sample of 813 patients with clinically deﬁnite
MS who, between March 2002 and March 2004, attended the
Dalhousie MS Research Unit, the only specialized referral service
for MS in Nova Scotia, Canada [27]. Each patient completed the
Health Utilities Index Mark 3 (HUI3) questionnaire within 16
days of a clinician-completed EDSS assessment. Previous studies
have demonstrated the reliability and validity of the HUI3 for use
in cost-effectiveness evaluations of MS therapies [28]. Complete
HUI3 and EDSS data were available for 784 patients. A previ-
ously described parametric function was ﬁtted to the data using
least squares minimization techniques [8]. The empirical and
modeled utility data by EDSS are shown in Figure 1; the ﬁgure
clearly shows that the modeled utility function provides a good
Table 2 Key model parameters
Relative hazard ratios for EDSS progression
Treatment strategy Distribution
Mean (standard error)
References
Placebo-controlled
evidence only
Mixed treatment
comparison model
IFNb-1a 6 MIU Lognormal 0.58 (0.19) 0.79 (0.12) [14–25]
IFNb-1a 22 mg Lognormal 0.72 (0.19) 0.72 (0.19)
IFNb-1a 44 mg Lognormal 0.60 (0.19) 0.70 (0.11)
IFNb-1b 8 MIU RRMS Lognormal 0.71 (0.18) 0.52 (0.09)
IFNb-1b 8 MIU SPMS Lognormal 0.72 (0.18) 0.72 (0.18)
GA 20 mg Lognormal 0.86 (0.23) 0.86 (0.23)
Relative risks of relapse
Treatment strategy Distribution
Mean (standard error)
Placebo-controlled
evidence only
Mixed treatment
comparison model
IFNb-1a 6 MIU Lognormal 0.82 (0.13) 0.83 (0.07) [14–25]
IFNb-1a 22 mg Lognormal 0.71 (0.08) 0.71 (0.08)
IFNb-1a 44 mg Lognormal 0.68 (0.08) 0.68 (0.05)
IFNb-1b 8 MIU RRMS Lognormal 0.70 (0.09) 0.66 (0.07)
IFNb-1b 8 MIU SPMS Lognormal 0.69 (0.09) 0.69 (0.09)
GA 20 mg Lognormal 0.70 (0.11) 0.70 (0.11)
Key cost model parameters
Treatment strategy Distribution Mean (standard error)
Constant parameter for linear EDSS-cost function Normal $3,126 ($1,500) Model based on [9,10]
Gradient parameter for linear EDSS-cost function
(per EDSS increase)
Normal $10,169 ($2,000) Model based on [9,10]
Cost per relapse Lognormal $3,158 ($4,000) [15,30]
Annual cost IFNb-1a 6 MIU n/a $12,438.57 (n/a) Provided by CMS
Annual cost IFNb-1a 22 mg n/a $13,965.83 (n/a)
Annual cost IFNb-1a 44 mg n/a $13,965.83 (n/a)
Annual cost IFNb-1b 8 MIU n/a $12,344.03 (n/a)
Annual cost GA 20 mg n/a $11,613.38 (n/a)
EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; IFNb, interferon beta; MIU, million international units; n/a, not applicable; RRMS, relapsing–remitting multiple sclerosis; SPMS,
secondary progressive multiple sclerosis.
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Figure 1 Empirical and modelled Health Utilities
Index Mark 3 (HUI3) utility data. EDSS, Expanded
Disability Status Scale.
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ﬁt to the data. The disutility associated with relapse was assumed
to be -0.22 for a mean duration of 46 days, based on the work
of Prosser [29]. In addition, treatment-related adverse events
were assumed to lead to a further utility decrement of 0.05, also
based on the previous work of Prosser [29]. In line with current
recommendations, health outcomes were discounted at a rate of
3%.
Dropouts
Published evidence suggests a dropout rate for all therapies of up
to around 30% during the trial durations; however, the evidence
on the distribution of dropouts over time is unclear. Evidence
from actual usage provided by two of the manufacturers of these
therapies suggested a slightly lower level of dropouts; however,
this was still over 20% [6]. The dropout estimates reported
within the trials and the company-generated dropout estimates
cannot be considered robust. The trial data include dropouts for
different reasons, some of which are protocol-related, while the
data on therapy cessation in clinical practice provide no infor-
mation on the reasons for dropout. As there appears to be little
signiﬁcant difference between treatment-related averse events or
their ease of use, it seems sensible to treat the therapies equally in
this regard. Therefore, the model assumes a dropout rate of 10%
in each of the ﬁrst 2 years, followed by a 3% dropout rate for
each subsequent year on therapy. The underlying assumption
is that there are a group of people who drop out early due to
treatment-related adverse events (10%), and a second group of
people who drop out later because either they or their doctors
feel that the therapy is not helping (10%). After that point, the
model assumes a long-term attrition each year in use consistent
with treatment compliance seen for the treatment of many
chronic conditions.
Resource Use and Costs
Costs included drug acquisition, administration, costs of MS care
according to EDSS disability, and costs associated with managing
MS relapse. All costs were valued in 2005 US dollars. Annual
drug and administration costs for the DMTs were obtained from
the CMS at manufacturers’ recommended doses. Evidence relat-
ing to the relationship between the degree of MS disability and
costs of care in the United States is limited. Consequently, EDSS-
speciﬁc costs of care were obtained from an analysis of data
collected within the Sonya Slifka database commissioned speciﬁ-
cally for use in this cost-effectiveness analysis. The Sonya Slifka
longitudinal study was established to study demographic, clinical
characteristics and disease course, resource utilization, health
provider and drug usage, as well as neurological, psychosocial,
and economic outcomes [10]. At the time of the analysis, the
Sonya Slifka study sample consisted of 2156 people with MS
who have been shown to be representative of the MS population
in the United States [10]. A subset of the wider Sonya Slifka
population, which included only those patients who represented
the Medicare population receiving these therapies, was included
in the analysis. The costs of care for RRMS and SPMS according
to the Activities of Daily Living (ADL) scale were obtained from
an analysis of a sample of the Sonya Slifka Longitudinal Multiple
Sclerosis database [9,10]. Resource use components included
hospitalizations, outpatient and emergency room visits, treat-
ments, laboratory tests, health-care professional visits, and medi-
cations. For the majority of resource utilization items, unit cost
estimates were obtained from Medicare claim ﬁles provided by
the CMS, while drug costs were obtained from the 2005 Red
Book.
The ADL cost proﬁle was mapped onto the EDSS by direct
comparison of the dimensions of the ADL and EDSS descriptive
systems. The mapping process involved identifying any ADL
categories and EDSS states that appeared to be direct or partial
matches; this was done independently by two of the study
authors (PT and CM). The two assessments were then compared
and an agreed descriptive mapping was produced. As the EDSS
has 20 states and ADL has only 9 states, it was necessary to map
individual ADL categories to more than one EDSS state. As the
Sonya Slifka data cover only a proportion of the range of EDSS
health states, an EDSS cost model was ﬁtted to the Sonya Slifka
data using linear regression techniques. Wide standard errors
were used to allow for uncertainty surrounding the Sonya Slifka
data itself and uncertainty surrounding the mapping process.
Further details of the mapping process are available from the full
study report [26].
The cost of managing mild, moderate, and severe relapses
was used to estimate a weighted mean cost for MS relapse, based
on a US costing study reported by O’Brien et al. [30] and the
relapse severity data observed within the clinical evidence base
[15]. All costs were discounted at a rate of 3%. The absence of
robust evidence on the relationship between the EDSS and the
costs of care in the United States is clearly a limitation of this
health economic analysis.
Initially, we intended to undertake the cost-effectiveness
analysis purely from the perspective of the CMS. Nevertheless,
the CMS perspective excludes the substantial nursing home costs
in later EDSS states, which would lead to an underestimate of the
cost savings attributable to delayed progression. Adopting the
CMS perspective would also lead to an imbalance in the analysis
as the quality of life gains associated with delayed progression
would still be considered in full. For these reasons, separate
cost-effectiveness scenarios are presented from the perspectives of
the US health-care payer and the CMS.
Cost-Effectiveness Analysis Scenarios and Probabilistic
Sensitivity Analysis
It is conventional practice in health economic evaluation to
compare the costs and effects of health interventions incremen-
tally, whereby interventions are ranked in order of effectiveness,
and cost-effectiveness ratios are calculated for nondominated
treatment options. Nevertheless, correlations between the efﬁca-
cies of the range of IFNbs and GA are unknown and have not
been fully evaluated within clinical trials; if one therapy is effec-
tive, it is possible that the other therapies are also effective.
Consequently, undertaking a full incremental analysis could lead
to one or more treatment options becoming dominated as a result
of differences in study populations or heterogeneities due to trial
design or reporting, rather than superior efﬁcacy. Given the
absence of evidence and the broad uncertainty surrounding cor-
relations between efﬁcacies, a standard incremental analysis is
unlikely to be helpful for policymakers. Instead, the costs and
outcomes associated with each treatment option were compared
marginally against the best supportive care option.
The evidence base for the effectiveness and cost-effectiveness
of disease-modifying treatments in MS is characterized by sub-
stantial uncertainty. First, the evidence used to inform the param-
eter values in the model is subject to uncertainty. There is further
uncertainty regarding usual clinical practice in the United States,
particularly concerning the appropriate disability cutoff for
therapy cessation. A ﬁnal form of uncertainty in the evidence
base regards the comparability of the efﬁcacy estimates for the
different treatments. While an intention-to-treat (ITT) estimate
of effectiveness has been published for the majority of the DMTs,
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the published estimate of effectiveness for 6 MIU IFNb-1a is
based on an analysis of data only for those patients who com-
pleted 2 years in the trial at which point it was stopped.
Cost-effectiveness was analyzed for four key scenarios:
1. Scenario 1: Evidence of effectiveness based exclusively upon
placebo-controlled evidence.
2. Scenario 2: Using a mixed treatment comparison model that
incorporates evidence from placebo-controlled trials and
head-to-head trials of IFNb.
3. Scenario 3: Treatment discontinuation upon progression to
EDSS 7.0.
4. Scenario 4: Analysis undertaken from the perspective of the
CMS, whereby costs are based on the empirical disease
management costs, which exclude costs associated with
nursing home care.
Probabilistic sensitivity analysis was undertaken to character-
ize the impact of parameter uncertainty surrounding the cost-
effectiveness of each of the DMTs. The results of this analysis
are presented using Cost-Effectiveness Acceptability Curves
(CEACs). These curves describe the probability that each treat-
ment option has a cost-effectiveness ratio that is better than a
range of willingness-to-pay thresholds as compared to best sup-
portive care. In other words, the CEACs describe the probability
that we would prefer a given treatment option over best support-
ive care according to how much we are willing to pay for each
additional QALY gained. CEACs are presented for each of the
four key cost-effectiveness scenarios.
Results
Central Estimates of Cost-Effectiveness
Table 3 presents the central estimates of cost-effectiveness for the
DMTs as compared to best supportive care for each of the four
key scenarios.
Based on the placebo-controlled evidence alone (Scenario 1),
the model analysis suggests that the marginal cost-effectiveness of
the DMTs is in the range $104,000 to $312,000 per QALY
gained. Crucially, the lowest cost-effectiveness estimate is based
on a trial which was not analyzed according to the ITT principle
and is likely to produce a systematically biased estimate of the
cost-effectiveness of this therapy. As demonstrated in Scenario 2,
the use of the modiﬁed relative relapse rates and relative hazards
of progression estimated using the mixed treatment comparisons
results in notably different estimates of cost-effectiveness. The
cost-effectiveness estimates for IFNb-1a 6 MIU appear markedly
less favorable than those estimated using the placebo-controlled
trial data. The marginal cost-effectiveness of IFNb-1a 6 MIU
versus best supportive care is in the range $104,000 to $111,000
per QALY gained when based on the placebo-controlled evidence
alone. When information from the head-to-head trials is used to
modify the estimated effectiveness of this therapy, the marginal
cost-effectiveness of IFNb-1a 6 MIU is estimated to be in the
range $218,000 to $234,000 per QALY gained. The results of the
head-to-head analysis of IFNb-1a 6 MIU are broadly consistent
with the UK commercial-in-conﬁdence ITT analysis of IFNb-1a
6 MIU, whereby the marginal cost-effectiveness ratio appears
considerably less economically attractive compared to the esti-
mate produced using the placebo-controlled trial estimates of
effectiveness [6–8]. Scenario 3 suggests that cessation of DMT
upon progression to EDSS 7.0 may produce more favorable
estimates of cost-effectiveness than those presented in Scenario 1;
under this scenario, the marginal cost-effectiveness estimates
for IFNb-1a 44 mg and IFNb-1b 8 MIU in RRMS are below
$100,000 per QALY gained. The analysis undertaken from the
CMS perspective (Scenario 4) led to a considerable reduction in
the absolute costs of all treatment options including best sup-
portive care; this resulted in only slightly less favorable estimates
of marginal cost-effectiveness for the DMTs.
Probabilistic Sensitivity Analysis Results
The results of the probabilistic sensitivity analysis are presented
as CEACs in Figure 2.
The economic analysis based on the placebo-controlled evi-
dence only (Scenario 1, Fig. 2a) suggests that the probability that
any of the therapies has a cost-effectiveness ratio that is better
than $60,000 per QALY gained as compared to best supportive
care is approximately 0.08 or lower. Figure 2b suggests that
when evidence from head-to-head trials is included in the
model analysis, the probability that these therapies have cost-
effectiveness ratio that is better than $60,000 per QALY gained
as compared to best supportive care is approximately 0.04.
Figure 2c suggests that stopping treatment upon progression to
EDSS 7.0 has a notably favorable impact upon cost-effectiveness;
the probability that any of these therapies has a cost-effectiveness
ratio that is better than $60,000 per QALY gained as compared
to best supportive care is approximately 0.47 or lower. Figure 2d
suggests that when the analysis is considered from the perspective
of the CMS, the probability that any of these therapies has a
Table 3 Central estimates of cost-effectiveness of disease-modifying therapies versus best supportive care
Treatment option
Marginal cost per QALY gained versus best supportive care
Scenario 1: Placebo-controlled
evidence, no treatment
discontinuation rule,
payer perspective
Scenario 2: Mixed treatment
comparisons, no treatment
discontinuation rule,
payer perspective
Scenario 3: Placebo-controlled
evidence, stop treatment
at EDSS 7.0, payer
perspective
Scenario 4: Placebo-controlled
evidence, no treatment
discontinuation rule,
CMS perspective
Physician-administered IFNb-1a
6 MIU
$111,138 $233,967 $66,082 $120,853
Self-administered IFNb-1a 6 MIU $103,762 $218,206 $60,052 $116,987
IFNb-1a 22 mg $189,174 $189,174 $120,688 $199,189
IFNb-1a 44 mg $128,728 $172,438 $79,002 $141,135
IFNb-1b 8 MIU for RRMS $158,466 $91,515 $97,382 $168,793
GA 20 mg $309,173 $309,173 $202,648 $316,128
IFNb-1b 8 MIU for RRMS
and SPMS
$312,344 $207,394 $122,202 $278,739
Best supportive care — — — —
CMS, Centers for Medicare and Medicaid Services; EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; IFNb, interferon beta; MIU, million international units; QALY, quality-adjusted
life-year; RRMS, relapsing–remitting multiple sclerosis; SPMS, secondary progressive multiple sclerosis.
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Figure 2 Cost-effectiveness acceptability curves
for disease-modifying therapies versus best sup-
portive care. (a) Scenario 1: Placebo-controlled
evidence, no stopping rule, health-care payer per-
spective; (b) Scenario 2: Mixed treatment com-
parisons, no stopping rule, health-care payer
perspective; (c) Scenario 3: Placebo-controlled evi-
dence, stop treatment at Expanded Disability
Status Scale 7.0, health-care payer perspective;
(d) Scenario 4: Placebo-controlled evidence, no
stopping rule, Centers for Medicare and Medicaid
Services perspective. GA, glatiramer acetate;
IFNb, interferon beta; MIU, million international
units; RRMS, relapsing–remitting multiple sclerosis;
SPMS, secondary progressive multiple sclerosis.
662 Tappenden et al.
cost-effectiveness ratio that is better than $60,000 per QALY
gained is close to zero.
Discussion
At the time of their introduction, IFNb and GA were considered
to be extremely expensive. Nevertheless, in the intervening years,
several more therapies have been launched with similar or even
higher costs. As a result of the associated cost pressures, health-
care systems are increasingly interested in assessing whether
treatments represent good value for money. The MRDD and the
new prescription drug beneﬁt increased CMS’ exposure to such
cost pressures.
Arguably, the most important ﬁnding is that in the US health-
care system, the DMTs could generate health beneﬁts at a
cost that could be considered cost-effective by certain decision-
makers. The marginal cost-effectiveness estimates for IFNb-1a
44 mg and IFNb-1b 8 MIU are below $100,000 per QALY gained
when treatment is stopped at EDSS 7.0. Interestingly, extending
treatment beyond this point signiﬁcantly increases the total
cost of care while producing very little additional health gain. A
second important ﬁnding is that when the evidence from the
head-to-head comparisons of the different treatments is synthe-
sized together with the placebo-controlled trial data, the esti-
mated efﬁcacy for IFNb-1a 6 MIU is substantially reduced, thus
having a markedly unfavorable impact upon its cost-effectiveness
proﬁle.
There remains substantial uncertainty surrounding the clini-
cal effectiveness and cost-effectiveness of the treatments consid-
ered in this analysis. The pivotal trials for these therapies were
relatively small in terms of the number of subjects, and adopted
remarkably short follow-up periods for a chronic condition. In
addition, the measurement properties of the outcome measure
are increasingly considered to be inadequate [31]. The absence of
high-quality data on the costs or quality of life associated with
MS, held in a form that can be linked to the effectiveness evidence
base, results in further uncertainty. We consulted long-term
observational studies of the DMTs to attempt to validate the
long-term predictions of the model [32]. However, where avail-
able, such studies were consistently subject to numerous impor-
tant methodological and statistical limitations, which may result
in confounding of outcomes [32]. Only one long-term study was
identiﬁed which prospectively evaluated EDSS outcomes beyond
10 years of follow-up [33]. This suggested that GA results in
long-term improvements in EDSS progression based on indirect
comparisons against longitudinal natural history studies. EDSS
outcomes were presented for patients remaining on GA
at 10 years and patients who were followed up but had since
withdrawn from therapy. However, patients who discontinued
treatment were not well represented in the sample, and the group
of patients still on treatment may be subject to a selection bias
when compared to natural history data. A tentative analysis
indicated that our model is more pessimistic, suggesting a typi-
cally faster rate of disease progression than that reported by Ford
et al. [33]. This result is to be expected, as the statistical analysis
of both the trial and the observational study assumes that MS
disability may improve while our model explicitly does not. As
Ford et al. [33] do not report the distribution of EDSS at
baseline, this ﬁnding is difﬁcult to conﬁrm. Had better
long-term data been available, we would have used this to inform
treatment efﬁcacy parameters rather than external model
validation.
A limitation of the analysis is the use of health utility
estimates sourced from patients in Canada rather than the United
States. While studies have presented preference-based health
utilities for MS patients in the United States, these have not
reported health utilities for individual EDSS states across the
entire spectrum of disability [34]. We compared the HUI3 utility
estimates to Euroqol-5D (EQ-5D) estimates for mild, moderate,
and severe MS reported by Kobelt et al. [34]. The HUI3 utilities
appear to be consistently lower than those reported by Kobelt
et al.: mild MS (HUI3 0.64 vs. EQ-5D 0.82); moderate MS
(HUI3 0.36 vs. EQ-5D 0.68); and severe MS (HUI3 0.19 vs.
EQ-5D 0.533). It is unclear whether these differences are driven
by the use of different HRQoL measurement and valuation
instruments, different cross-sections of disability at the point of
evaluation or real differences in quality of life between patients in
different geographical locations. Reanalysis of our model using
the banded utility estimates reported by Kobelt et al. did not
dramatically inﬂuence the cost-utility results; under Scenario 1,
the marginal cost-utility of the DMTs ranged from $115,000 to
315,000 per QALY gained.
An innovative aspect of our study has been the use of Baye-
sian evidence synthesis methods to obtain comparable estimates
of the effectiveness of the DMTs. While the assumptions required
to undertake this type of analysis require caution in their inter-
d
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pretation, and the evidence base can be synthesized using a
variety of methods, the results of this analysis are consistent with
the hypothesis that non–intention-to-treat analyses will overstate
the effectiveness and thus the cost-effectiveness of interventions.
This, in turn, suggests that the estimated cost-effectiveness
of 6 MIU IFNb-1a presented within Scenario 1 should be
approached with caution as the trial was not undertaken accord-
ing to the ITT principle. Despite having been available for nearly
two decades, the evidence base for the effectiveness and cost-
effectiveness of DMTs in RRMS and SPMS remains poor. Of
particular concern is the lack of an ITT estimate of the efﬁcacy of
IFNB-1a 6 MIU obtained from a substantial randomized con-
trolled trial (RCT). Furthermore, the use of a short follow-up
duration within all of the trials results in a considerable degree
of uncertainty surrounding the long-term effectiveness of these
therapies.
There are a number of areas in which further research is
warranted.
1. Existing RCTs of IFNb and GA have used trial durations of
between 9 months [14] and 5 years [15]. Further research
concerning the impact of the DMTs on disease progression
and relapse would be of considerable value. However, direct
observational studies of MS are particularly expensive
in terms of both ﬁnancial cost and study follow-up
requirements.
2. There is a dearth of evidence concerning the effectiveness of
sequences of these therapies. The health economic analysis
presented within this study does not include the possibility
of switching between therapies. Further research concerning
the clinical effectiveness and cost-effectiveness of alternative
sequences of DMTs is merited.
3. The Sonya Slifka data set [9,10] is clearly a rich and valu-
able source of health-care utilization data for individuals
with MS. However, the transposition of these resource use
data, which are based on a speciﬁc ADL scale, onto the
EDSS is problematic. The absence of robust cost evidence to
inform cost-effectiveness analysis has been noted within
previous cost-effectiveness models developed in the United
States [29]. Further research on the relationship between the
EDSS, health-care utilization, and costs of MS care would
be highly informative for further economic evaluations.
4. While the Canadian HUI3 data [27] used within this analy-
sis are highly consistent with other utility sources from
other countries, US valuations may differ from those used in
this analysis. Further information concerning the relation-
ship between EDSS and health utilities within the US Medi-
care population may be valuable.
Conclusion
Further research is required to examine the long-term clinical
effectiveness and cost-effectiveness of these therapies. There is
no deﬁnitive guidance in the United States concerning disconti-
nuation of DMTs; this study suggests that the prudent use
of a treatment discontinuation rule may improve the cost-
effectiveness of DMTs.
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